Cardiovascular access and device delivery system

Information

  • Patent Grant
  • 11653948
  • Patent Number
    11,653,948
  • Date Filed
    Thursday, August 13, 2020
    3 years ago
  • Date Issued
    Tuesday, May 23, 2023
    11 months ago
Abstract
A system and method of accessing a heart of a patient is provided. A cardiac access channel is established through an apical wall of the heart to provide direct access through the apical wall to the left ventricle. A vascular access channel is established through the skin to a peripheral blood vessel. A first end of an elongate member is advanced from the outside of the apical wall through the cardiac access channel and into the left ventricle. A second end disposed opposite the first end remains outside the patient. The elongate member is drawn into and through the vascular access channel to externalize the first end of the elongate member while leaving the second end outside the apical wall of the heart.
Description
BACKGROUND OF THE INVENTION
Field of the Invention

This application is directed to systems and methods for accessing heart chambers or major blood vessels to facilitate delivering and implanting devices or performing therapies therein.


Description of the Related Art

Catheters are in widespread use for a wide number of procedures. In recent years, complex devices such as aortic valves have been delivered using catheters. These catheter based procedures provide benefits for patients, including reduced trauma compared to surgical techniques for accomplishing similar outcomes, e.g., aortic valve replacement.


Limitations of catheter based techniques have spurred efforts to develop a less invasive surgical technique that can be performed through cannulae inserted into the heart through the chest wall and through an apical puncture in the heart. These procedures have advantages, such as moving the proximal end of the tools used to perform the procedure closer to the surgical site.


These surgical approaches provide various disadvantages, however. For one, access to the heart through the chest wall is more complex than access to a superficial peripheral vessel, such as a femoral artery. For example, a surgical window must still be opened to advance the surgical cannulae through the skin and intervening tissue to the heart. To the extent large devices are delivered through this enlarged surgical window, trauma to the patient is increased and closure of the heart puncture is challenging.


SUMMARY OF THE INVENTION

The methods and systems herein provide low-profile access for creating a trans-cardiac rail with two externalized ends.


In one embodiment, a method of accessing a heart of a patient is provided. The method can be used to provide a treatment, which may involve implanting a prosthesis or other implant. A cardiac access channel is established through an apical wall of the heart to provide direct access through the apical wall to the left ventricle. A vascular access channel is established through the skin to a peripheral blood vessel. A first end of an elongate member is advanced from the outside of the apical wall through the cardiac access channel and into the left ventricle. A second end disposed opposite the first end remains outside the patient. The elongate member is drawn into and through the vascular access channel to externalize the first end of the elongate member while leaving the second end outside the apical wall of the heart.


In another embodiment, a method of accessing a heart is provided. Vascular access is provided at a peripheral vein. An access catheter is advanced through the peripheral vein, through the vena cava, and into the heart. A distal portion of the access catheter is advanced across the intra-atrial septum into the left atrium. A channel is established through a wall of the heart to provide direct access through the wall to the left ventricle. An elongate member is advanced through the channel into the left ventricle. The elongate member is drawn into the access catheter. The elongate member is tensioned between the distal portion of the access catheter and the channel.


In another embodiment, a method of accessing a heart is provided. Vascular access is provided at a peripheral artery. An access catheter is advanced into the aorta through the peripheral artery. In some embodiments, the access catheter passes through the brachial artery and the left subclavian artery. In some embodiments, the access catheter passes through a femoral artery and an iliac artery. In some embodiments, the elongate member advances antegrade from the ventricle into the aorta. In some embodiments, the elongate member advances into the subclavian artery or iliac artery. In at least one embodiment, the elongate member includes an atraumatic tip such as a floppy tip, a “J” tip, or a balloon tip.


In another embodiment, a method of placing a cardiovascular prosthesis is provided. A delivery system is advanced percutaneously from a peripheral blood vessel access site into the left atrium of a heart. The left ventricle is accessed from outside the heart through the wall of the heat at or adjacent to the apex of the heart by placing a sheath therethrough. An elongate member is advanced through the sheath across the aortic valve. The delivery system is linked with the elongate member to provide a venous-arterial rail for delivery of a prosthesis into the heart and/or the aorta. A condition in the heart and/or arterial vasculature is treated over the venous-arterial rail.


In another embodiment, a device for closing a cardiac access channel is provided. The device comprises an elongate body having a proximal end and a distal end. The proximal end has a first opening for delivering a closure medium and a second opening for delivering a pressurizing medium. The distal end has a first fillable member that comprises a distal face, an enclosure disposed at the distal face and extending proximally therefrom, and one or more pores disposed through the enclosure at the distal face thereof. The first fillable member is in fluid communication with the first opening such that the closure medium can be delivered to the first fillable member. The distal end has a second fillable member in fluid communication with the second opening such that the pressuring medium can be delivered to the second fillable member. The first and second fillable members are arranged such that when the first fillable member contains the closure medium and the second fillable member contains the pressurizing medium, the closure medium is disposed through the pore(s).





BRIEF DESCRIPTION OF THE DRAWINGS

A more complete appreciation of the subject matter of this application and the various advantages thereof can be realized by reference to the following detailed description, in which reference is made to the accompanying drawings in which:



FIG. 1 is a cross-sectional view of a heart showing a needle placed through the apex of the heart into the left ventricle to provide access to the ventricle;



FIG. 2 shows an elongate member disposed through the needle and into the left ventricle;



FIG. 3 illustrates an introducer sheath disposed transapically over the elongate member into the ventricle;



FIG. 4 illustrates an access catheter disposed from venous vasculature into the heart;



FIG. 5 illustrates the elongate member illustrated in FIG. 2 engaged by a snare and drawn toward or into the access catheter of FIG. 4 to provide a delivery platform through the mitral valve;



FIG. 6 illustrates providing a delivery platform between a direct heart access and one or more of a plurality of possible peripheral arterial sites,



FIG. 7 illustrates removing the introducer sheath leaving the elongate member in place;



FIG. 8 illustrates placing a closure device over the elongate member to a position adjacent to the epicardium;



FIG. 9 illustrates one embodiment of a closure device configured to facilitate closure of a small puncture of the apex of the heart wall;



FIG. 10 illustrates another embodiment of a closure device that includes a disc shaped balloon to reduce or eliminate bleeding through the heart wall into the pericardium;



FIG. 11 illustrates another embodiment of a closure device, having a dual chamber configuration to dispense a closure medium;



FIG. 12 illustrates a configuration of the closure device of FIG. 10 showing an outer chamber having a closure medium disposed therein and an inner chamber being in a low profile states;



FIG. 13 illustrates the closure device of FIG. 10 with the inner chamber in a high profile state, e.g., inflated, to enhance the pressure in the outer chamber;



FIG. 14 illustrates the closure device of FIG. 10 with the inner chamber in a further high profile state, e.g., further inflated, to cause the closure medium to seep out of a distal face of the outer chamber;



FIG. 15-17 illustrate providing a delivery platform between peripheral venous and peripheral arterial access sites, facilitated by direct heart access; and



FIGS. 18 and 19 illustrates providing two elongate members that can act as guidewire with independent maneuverability.





More detailed descriptions of various embodiments of catheter based and transapical delivery systems, components and methods useful to treat patients are set forth below.


DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

This application discloses various system and methods for providing a rail structure for guiding the advancement and deployment of cardiac prostheses or therapy devices. The rail structure preferably has two or more ends that are externalized. Externalized ends may include portions that are disposed outside the body, such as through percutaneous vascular access device or through direct cardiac access device. Intracorporeal lengths of the rail may be disposed between the externalized ends. FIGS. 1-5 illustrate systems and methods that provide a rail structure between a direct heart access and a peripheral blood vessel access site. FIG. 6 shows a variation where a rail structure is disposed between a direct heart access and a peripheral arterial access. FIGS. 7-14 illustrate systems and methods for closing a heart wall puncture. FIGS. 15-19 illustrate systems and methods that can be used to provide a rail between an externalized end at a peripheral venous site and an externalized end at a peripheral arterial site. The methods and systems of FIGS. 15-19 exploit the use of direct heart access to facilitate various techniques.


I. Direct Heart Access to Facilitate a Venous-to-Apex or Arterial-to-Apex Rail


FIGS. 1-6 illustrate a method of accessing a heart. FIG. 1 illustrates a channel 2 established through a wall of the heart to provide direct access through the wall to the left ventricle 4. Prior to establishing the channel 2 through the heart, surgical access is provided to the outside of the heart. For example, a minimally invasive technique can be provided to expose the apex of the heart. The minimally invasive technique may involve spreading two or more ribs to provide for direct visualization of the heart. In some embodiments, the channel 2 is established with a small-profile needle 6. That is, the needle 6 may be inserted from the outside of the heart through the myocardium and into the left ventricle as shown. In at least one embodiment, the channel 2 is established using an 18-gauge, beveled needle. In some embodiments, the needle 6 includes a collapsible sheath to establish the channel 2 through the heart wall.



FIG. 2 shows an elongate member 10 advanced through the channel 2 into the left ventricle 4. For example, the elongate member 10 can be inserted such that a distal end thereof is advanced through the needle 6 into the ventricle as shown. The proximal end can remain outside the patient at this stage. The elongate member 10 can be similar to a stiff guidewire. In some embodiments, the elongate member 10 has a flow directed device such as a small balloon disposed at the distal end thereof.



FIG. 3 shows the needle 6 can be removed after the elongate member 10 is advanced into the left ventricle 4. In some embodiments, an introducer sheath or other spanning sheath 12 is fitted over the elongate member 10 and advanced over the elongate member 10 until the spanning sheath 12 spans across the heart wall. In some embodiments, the spanning sheath 12 is a low-profile sheath. In some embodiments, the spanning sheath is a 4 or a 5 French sheath. In some embodiments, the spanning sheath is 16-gauge or 18-gauge. Preferably the spanning sheath 12 is configured to limit or prevent backflow of blood out of the ventricle which is a high pressure chamber.



FIGS. 4-6 illustrate methods of vascular access, whereby an access catheter can be advanced from a peripheral venous site to the heart. FIG. 4 illustrates an access catheter 14 advanced through venous vascular path, e.g., from a femoral or other peripheral vein, through the inferior or superior vena cava, and into the heart.



FIG. 5 shows a distal portion 16 of the access catheter 14 is advanced across the intra-atrial septum into the left atrium 20. In one method, the elongate member 10 is drawn into the access catheter 14. In some embodiments, the distal portion 16 of the access catheter 14 may include a means for capturing the elongate member 10. In at least one embodiment, a snare 30 extends from the distal portion 16 of the access catheter 14 and entraps or captures the elongate member 10. The elongate member 10 is then drawn into the access catheter 14. The elongate member 10 can be tensioned between the distal portion 16 of the access catheter 14 and the channel 2. Alternatively, the access catheter 14 may be modified such as by being shortened and/or equipped with appropriate valves to be introduced through the left atrial wall using access methods discussed in U.S. Patent Application Publication Number US 2013/0041395, which is incorporated herein by reference. Further details of performing procedures using a taught platform between the access catheter 14 as illustrated or modified and a ventricle wall (e.g., with a base or footing deployed adjacent to an inner surface of the ventricle wall, with tines at least partially embedded in the wall, or with a trans-apical channel) are discussed in International Publication Number WO 2014/138284, which is incorporated herein by reference.


In some embodiments, the venous-to-apex rail is used to deploy a prosthesis (not shown) to the mitral valve 25. A venous-to-apex rail is established as shown above in FIG. 5. Tension is applied through the elongate member 10 in the apical direction, e.g., by pulling on the proximal externalized end, to draw the prosthesis from the access catheter 14. In some embodiments, the prosthesis is delivered by a second catheter (not shown), which is threaded over the venous-to-apex rail. In at least one embodiment, the venous-to-apex rail passes through the lumen of the prosthesis and is used to assist in seating the prosthesis onto the mitral valve 25. In some embodiments, the prosthesis is deployed between the anterior and posterior mitral valve leaflets at the level of the mitral valve annulus. In at least one embodiment, the prosthesis is deployed by expanding a balloon within the lumen of the prosthesis to seat the prosthesis in the mitral valve annulus. In some embodiments, the prosthesis is deployed by retracting a sheath to expose the prosthesis and to permit the prosthesis to expand into secure engagement with the mitral valve annulus.


In some embodiments, the venous-to-apex rail is used to deploy an annuloplasty ring. Annuloplasty rings are discussed in U.S. Pat. No. 5,888,240, which is incorporated herein by reference. In some embodiments, an annuloplasty ring is deployed alternatively or in addition to seating a prosthesis onto the mitral valve 25.



FIG. 6 illustrates alternative embodiment, in which a rail with two externalized ends is provided between the apical access site discussed above and a peripheral artery. A path 14′ is shown, through which the elongate member 10 can travel to establish a rail that can be externalized at a peripheral artery. An arterial access catheter disposed at a peripheral location is advanced through the skin disposed over a peripheral artery and into the peripheral artery. In some embodiments, the arterial access catheter is introduced at a brachial artery and can be passed through the left subclavian artery 20, as illustrated in FIG. 6 by the solid line that extends through the left subclavian artery 20. In at least one embodiment, the arterial access catheter can be introduced at a femoral artery, and passed through the iliac artery 26, as illustrated in FIG. 6 by the dashed line that extends through the iliac artery 26. In some embodiments, the elongate member 10 is advanced antegrade into the aorta and/or into more distal arteries, to be drawn into the arterial access catheter. In some embodiments, the elongate member 10 is advanced antegrade into the subclavian artery 20, where a snare disposed through the arterial access catheter couples with elongate member 10. In at least one embodiment, the elongate member 10 is advanced antegrade into the iliac artery 26, where a snare disposed through the arterial access catheter couples with elongate member 10. After the snare or other capturing device disposed through the access catheter couples with the elongate member 10, the distal end of the elongate member 10 is drawn out of (e.g., externalized at) the arterial access site.


Thus, the path 14′ defines two example routes for an apex to arterial rail structure. The route to the subclavian artery 20 is advantageous in providing a straighter path and is more suitable for smaller and/or lower profile devices. The route to the iliac artery 26 is advantageous for larger and/or higher profile devices that, by virtue of the rail structure provided by the elongate member 10, can easily track the relatively more tortuous path to the heart. Other peripheral sites could be used to externalize the distal end of the elongate member 10.


II. Closure Systems and Methods for Small-Bore Apex Access


FIGS. 7-14 show methods for closing the apical site through which the elongate member 10 entered the left ventricle 4. FIG. 7 shows that in one method the spanning sheath 12 is first removed from the apex of the left ventricle 4. If no bleeding results after removal of the spanning sheath 12, the elongate member 10 is then removed from the heart. In some embodiments, the myocardium is sutured at the site of apical access to compress the tissue and close the site of apical access.



FIGS. 8-14 show methods for reducing bleeding that follows removal of the spanning sheath 12. FIG. 8 illustrates an embodiment where a compression member 32 is advanced over the proximal portion of the elongate member 10 until the compression member 32 contacts the heart. In some embodiments the compression member 32 includes means to introduce biological glue onto the epicardial surface 34 of the left ventricle 4. In some embodiments, the compression member 32 is held against the epicardial surface 34 for 30 seconds to 5 minutes to reduce bleeding. After bleeding has been reduced, the compression member 32 is withdrawn from epicardial surface 34 and the elongate member 10 is removed from the heart.



FIG. 9 illustrates various configurations of the compression member 32. In some embodiments, the compression member 32 is blunt-tipped. In some embodiments, the compression member 32 is disc-shaped.



FIGS. 10-14 illustrate a device 40 for closing a cardiac access channel 2. The device 40 provides for controlled dispensing of a closure medium in the pericardium or onto the epicardium. Referring to FIGS. 11 and 12, the device 40 comprises an elongate body 42 having a proximal end 44 and a distal end 46. The proximal end 44 has a first opening 50 for delivering a closure medium and a second opening 52 for delivering a pressurizing medium. The distal end 46 has a first fillable member 54 that comprises a distal face 56, an enclosure 58 disposed at the distal face 56 and extending proximally therefrom, and one or more pores 60 disposed through the enclosure 58 at the distal face 56 thereof. In some embodiments, the distal face 56 has first and second traverse dimensions 53, 55 that are larger than cardiac access channel to be closed. In at least one embodiment, the first and second traverse dimensions 53, 55 are at least four times the size of the cardiac access channel to be closed. In at least one embodiment the first and second traverse dimensions 53, 55 are at least 12 mm.


The first fillable member 54 is in fluid communication with the first opening 50 such that the closure medium can be delivered to the first fillable member 54. The distal end 46 has a second fillable member 62 in fluid communication with the second opening 52 such that the pressuring medium can be delivered to the second fillable member 62. The first and second fillable members 54, 62 are arranged such that when the first fillable member 54 contains the closure medium and the second fillable member 62 contains the pressurizing medium, the closure medium is disposed through the pore(s) 60.


III. Direct Heart Access to Facilitate a Venous-Arterial Rail


FIGS. 15-19 illustrate a method of placing a cardiovascular prosthesis that can be used for cardiac devices and also for deploying devices in the aorta and other large vessels close to the heart. A delivery system 70 is advanced percutaneously from a peripheral blood vessel access site into the left atrium of a heart. The left ventricle is accessed from outside the heart through the wall of the heart at or adjacent to the apex of the heart by placing a spanning sheath 12 therethrough. An elongate member 10 is advanced through the spanning sheath 12. An arterial access catheter is introduced into or through a peripheral artery. The elongate member 10 is advanced antegrade, and is captured by or through the access catheter, for example by a snare that couples with the elongate member 10, as described above. The elongate member 10 is drawn into the arterial access catheter after traversing one branch of the path 14′ (e.g., into the subclavian or into the iliac). FIG. 16 shows that the elongate member 10 is also captured by a snare or loop 72 or similar structure that is extended from the distal portion 16 of the access catheter 14. FIG. 16 shows the delivery system 70 is linked with the elongate member 10 to provide a venous-arterial rail for delivery of a prosthesis into the heart and/or the aorta.


In some embodiments, the delivery system 70 accesses the left atrium through the left atrial wall using methods discussed in U.S. Patent Application Publication Number US 2013/0041395, which is incorporated herein by reference. In some embodiments, a delivery system 70 that accesses the left atrium through the left atrial wall is used to deploy a taught ventricular platform extending to a position adjacent an inner wall of the ventricle, extending to a position at least partially embedded in a wall about a ventricle, or extending completely through a ventricle wall as in a transapical channel as discussed in International Publication Number WO 2014/138284, which is incorporated herein by reference.



FIGS. 17-19 illustrate treating a condition in the heart and/or arterial vasculature over the venous-arterial rail. The loop 72 of delivery system 70 links to the elongate member 10. In some embodiments, the delivery system 70 links to the elongate member 10 subsequent to the elongate member 10 coupling with the arterial access catheter. In some embodiments, the delivery system 70 links to the elongate member 10 before the elongate member 10 has coupled to the arterial access catheter. In some embodiments, tension in the proximal end of the feed wire 74 is reduced to allow the wire 74 to extend from the delivery system 70 and to track along the elongate member 10 into the arterial vasculature. In the arterial vasculature, the feed wire 74 follows and may in some cases couple with the elongate member 10 along the path 14′, as described above. Tension can be applied from outside the cardiac access site to the elongate member 10 to draw the feed wire 74 from the delivery system 70 and into the ventricle 4. Further tension on the elongate member 10 can cause the prosthesis 80 (discussed below) to be drawn out of the delivery system 70. Tension on the elongate member 10 applied at a distal arterial site (e.g., on an externalized distal end of the elongate member 10 after the elongate member 10 has traversed one of the branches of the path 14′) can draw the feed wire 74 and/or the prosthesis 80 through the aortic valve 24 and/or to the peripheral artery.


In some embodiments, a prosthesis 80 is delivered to the heart through the delivery system 70. In at least one embodiment, tension is applied through the elongate member 10 from a proximal externalized end of the elongate member 10 in the apical direction to draw the prosthesis 80 from the delivery system 70. After the prosthesis 80 enters the left ventricle 4, tension is applied to the elongate member 10 from a distal externalized end of the elongate member 10 that has been externalized after following a branch of the path 14′ to draw the prosthesis 80 into or through the aortic valve 24. Thereafter, the prostheses 80 can be deployed in the aortic valve space or in the vasculature, e.g., in the ascending aorta. In some embodiments, the prosthesis 80 is deployed in the aortic valve annulus. In FIG. 19, the feed wire 74 extends through the lumen of the prosthesis 80, while the elongate member 10 is outside the lumen of the prosthesis 80. In some embodiments, the prosthesis 80 is positioned at the aortic valve 24 and held in place while the elongate member 10 is withdrawn from the aortic valve 24. In some embodiments, the prosthesis 80 is held in place by partially deploying the prosthesis 80. The prosthesis 80 can be self-expandable such that withdrawal of a sheath permits a portion or all of the prosthesis 80 to expand. The prosthesis 80 can be secured to the elongate member 10 while a sheath retaining the prosthesis 80 in a low-profile configuration is withdrawn. As the sheath is withdrawn, the prosthesis 80 is permitted to expand and does expand by virtue of an elastic or shape memory material or member forming a part thereof. The prosthesis 80 could be mounted on a balloon or other expandable member capable of deploying the prostheses 80. In some embodiments, the elongate member 10 is withdrawn from the aortic valve 24 by drawing the elongate member 10 toward the peripheral arterial access site along one of the branches of the path 14′ e.g., by pulling on the distal externalized end. In some embodiments, the elongate member 10 is withdrawn from the aortic valve 24 by disengaging the elongate member 10 from the feed wire 74 and pulling on the proximal externalized end of the elongate member 10 and in the apical direction.


In some embodiments, an over-the-wire catheter is used to move the prosthesis 80 along the venous-to-apex rail, along the apex-to-arterial rail, or along the venous-to-arterial rail. The rail can be pulled tight to straighten the rail in certain segments, e.g., from the heart apex through the aortic valve or through the mitral valve. In some embodiments, the prosthesis 80 is coupled to the feed wire 74 and pulled along with the rail. The prosthesis 80 may be coupled to the feed wire 74 by a variety of methods including releasably attaching or crimping onto the feed wire 74 a retaining platform (not shown) that temporarily holds the prosthesis 80 in an undeployed configuration. In other words, systems and method disclosed herein can have a first configuration or mode where a rail can be held stationary, while permitting a catheter or other device that may carry the prosthesis 80 to move relative to the rail such that the catheter, device or prosthesis can be advanced or retracted over the rail. The systems and method herein can have a second configuration or mode where the rail can be coupled to a catheter, device or prosthesis for no relative movement between the rail and the catheter, device or prosthesis such that the rail can be moved through the patient carrying the catheter, component and/or prosthesis. The first configuration can provide a direct push-pull mode. The second configuration can provide an indirect push-pull mode. The second configuration also enable the catheter, device or prosthesis to be pulled from distal a target site or proximal of a target site.


The prosthesis 80 may also be introduced to the heart using methods such as those described in International Application Number PCT/US2014/041366, which is incorporated herein by reference.


Although the present invention has been disclosed with reference to certain specific embodiments of devices and methods, the inventors contemplate that the invention more broadly relates to methods disclosed above, such as those useful for orienting a catheter with respect to an anatomical structure, as well as performing diagnostic and/or therapeutic procedures in the heart or adjacent the heart. For instance, one could place a treatment device, including a stent-graft, in the ascending aorta, the aortic root, the descending aorta, or the abdominal aorta. Accordingly, the present invention is not intended to be limited to the specific structures and steps disclosed herein, but rather by the full scope of the attached claims.

Claims
  • 1. A system for accessing a heart of a patient, comprising: a cardiac access sheath having a channel therein and a distal end configured to be advanced through an apical wall of the heart to provide direct access via the channel through the apical wall to the left ventricle of the heart;an arterial access catheter having a distal end configured to be advanced toward the heart of the patient;a venous access catheter having a distal end configured to be advanced from a peripheral venous site through an intra-atrial septum and into a left atrium; anda rail having a first end configured to be inserted into the patient through the channel of the cardiac access sheath and to couple with the arterial access catheter, the rail having an intermediate portion and a second end opposite the first end, the first end configured to be advanced through the arterial access catheter to be disposed outside a patient through a first percutaneous access site while the intermediate portion is disposed in a chamber of the heart and while the second end is disposed outside the patient through the apical wall of the heart; anda snare configured to be advanced within the venous access catheter to extend from the venous access catheter to capture the intermediate portion of the rail between the cardiac access sheath and the arterial access catheter after the first end of the rail has coupled with the arterial access catheter.
  • 2. The system of claim 1, wherein the cardiac access sheath comprises a sharp distal portion configured to pierce a wall of the heart.
  • 3. The system of claim 1, wherein the intermediate portion of the rail is configured to extend from a radial artery, through the heart, to a peripheral vein.
  • 4. The system of claim 1, wherein the intermediate portion of the rail is configured to extend from a femoral artery, through the heart, to a peripheral vein.
  • 5. The system of claim 1, wherein the intermediate portion of the rail is configured to extend from a transapical access point to a peripheral vein.
  • 6. The system of claim 1, wherein the intermediate portion of the rail is configured to extend from a transapical access point to a peripheral artery.
  • 7. The system of claim 1 further comprising a device for closing a cardiac access channel, comprising: an elongate body having a proximal end and a distal end;the proximal end having a first opening for delivering a closure medium and a second opening for delivering a pressurizing medium;the distal end having a first fillable member comprising a distal face, an enclosure disposed at the distal face and extending proximally therefrom, and one or more pores disposed through the enclosure at the distal face thereof, the first fillable member being in fluid communication with the first opening such that the closure medium can be delivered to the first fillable member;the distal end having a second fillable member in fluid communication with the second opening such that the pressurizing medium can be delivered to the second fillable member;wherein the first and second fillable members are arranged such that when the first fillable member contains the closure medium and the second fillable member contains the pressurizing medium, the closure medium is disposed through the pore(s) one or more pores.
  • 8. The system of claim 7, wherein the second fillable member is at least partially disposed within a volume of the first fillable member.
  • 9. The system of claim 7, wherein the one or more pores disposed through the enclosure at the distal face of the first fillable member comprises an array of pores having first and second transverse dimensions of at least four times the size of the cardiac access channel to be closed.
  • 10. The system of claim 7, wherein the first and second dimensions are at least 12 mm.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. patent application Ser. No. 15/525,914, filed May 10, 2017, which is a national stage application under 35 U.S.C. § 371 of International Application No. PCT/US2015/060726, filed on Nov. 13, 2015, which published in English as WO 2016/077783 A1 on May 19, 2016, and which claims priority benefit of U.S. patent application Ser. No. 62/079,811, filed on Nov. 14, 2014.

US Referenced Citations (164)
Number Name Date Kind
4777951 Cribier et al. Oct 1988 A
5171259 Inoue Dec 1992 A
5201880 Wright et al. Apr 1993 A
5573540 Yoon Nov 1996 A
5575799 Bolanos et al. Nov 1996 A
5609598 Laufer et al. Mar 1997 A
5626588 Sauer et al. May 1997 A
5716367 Koike et al. Feb 1998 A
6029671 Stevens et al. Feb 2000 A
6051014 Jang Apr 2000 A
6090096 St. Goar et al. Jul 2000 A
6117144 Nobles et al. Sep 2000 A
6117145 Wood et al. Sep 2000 A
6136010 Modesitt et al. Oct 2000 A
6165183 Kuehn et al. Dec 2000 A
6197043 Davidson Mar 2001 B1
6206893 Klein et al. Mar 2001 B1
6269819 Oz et al. Aug 2001 B1
6287321 Jang Sep 2001 B1
6312446 Huebsch et al. Nov 2001 B1
6312447 Grimes Nov 2001 B1
6325067 Sterman et al. Dec 2001 B1
6328757 Matheny Dec 2001 B1
6461366 Seguin Oct 2002 B1
6508828 Akerfeldt et al. Jan 2003 B1
6575971 Hauck et al. Jun 2003 B2
6629534 St. Goar et al. Oct 2003 B1
6635068 Dubrul et al. Oct 2003 B1
6752813 Goldfarb et al. Jun 2004 B2
6770083 Seguin Aug 2004 B2
6926715 Hauck et al. Aug 2005 B1
6932792 St. Goar et al. Aug 2005 B1
6945978 Hyde Sep 2005 B1
7048754 Martin et al. May 2006 B2
7226467 Lucatero et al. Jun 2007 B2
7276078 Spenser et al. Oct 2007 B2
7404824 Webler et al. Jul 2008 B1
7563267 Goldfarb et al. Jul 2009 B2
7569062 Kuehn et al. Aug 2009 B1
7604646 Goldfarb et al. Oct 2009 B2
7632308 Loulmet Dec 2009 B2
7635329 Goldfarb et al. Dec 2009 B2
7666204 Thornton et al. Feb 2010 B2
7704269 St. Goar et al. Apr 2010 B2
7736388 Goldfarb et al. Jun 2010 B2
7811296 Goldfarb et al. Oct 2010 B2
7828819 Webler et al. Nov 2010 B2
7854762 Speziali et al. Dec 2010 B2
7938827 Hauck et al. May 2011 B2
7981123 Seguin Jul 2011 B2
8052592 Goldfarb et al. Nov 2011 B2
8123703 Martin et al. Feb 2012 B2
8172856 Eigler et al. May 2012 B2
8216256 Raschdorf, Jr. et al. Jul 2012 B2
8216302 Wilson et al. Jul 2012 B2
8303608 Goldfarb et al. Nov 2012 B2
8323334 Deem et al. Dec 2012 B2
8382796 Blaeser et al. Feb 2013 B2
8409219 Kelley et al. Apr 2013 B2
8409273 Thornton et al. Apr 2013 B2
8545551 Loulmet Oct 2013 B2
8568472 Marchand et al. Oct 2013 B2
8920463 McGukin, Jr. et al. Dec 2014 B2
8932325 Stanley et al. Jan 2015 B2
8992605 Zakai et al. Mar 2015 B2
9023099 Duffy et al. May 2015 B2
9060858 Thornton et al. Jun 2015 B2
9474605 Rowe et al. Oct 2016 B2
9498330 Solem Nov 2016 B2
9763658 Eigler et al. Sep 2017 B2
10080657 Siegel Sep 2018 B2
10105221 Siegel Oct 2018 B2
10478304 McNiven et al. Nov 2019 B2
10499905 Eigler et al. Dec 2019 B2
10758241 Lashinski et al. Sep 2020 B1
10758265 Siegel Sep 2020 B2
10799359 Siegel et al. Oct 2020 B2
10898323 Siegel Jan 2021 B2
11241308 Siegel et al. Feb 2022 B2
11291544 Siegel et al. Apr 2022 B2
11439501 Siedel et al. Sep 2022 B2
20010005787 Oz et al. Jun 2001 A1
20020013571 Goldfarb et al. Jan 2002 A1
20030120340 Liska et al. Jun 2003 A1
20040044350 Martin et al. Mar 2004 A1
20040260322 Rudko et al. Dec 2004 A1
20050033446 Deem et al. Feb 2005 A1
20050107871 Realyvasquez et al. May 2005 A1
20050143811 Realyvasquez Jun 2005 A1
20050222489 Rahdert et al. Oct 2005 A1
20050273135 Chanduszko et al. Dec 2005 A1
20060004442 Spenser et al. Jan 2006 A1
20060020275 Goldfarb et al. Jan 2006 A1
20060074484 Huber Apr 2006 A1
20060089671 Goldfarb et al. Apr 2006 A1
20060229708 Powell et al. Oct 2006 A1
20060241745 Solem Oct 2006 A1
20060293739 Vijay Dec 2006 A1
20070032850 Ruiz et al. Feb 2007 A1
20070038293 St.Goar et al. Feb 2007 A1
20070055303 Vidlund et al. Mar 2007 A1
20070093890 Eliasen et al. Apr 2007 A1
20070198082 Kapadia et al. Aug 2007 A1
20070255273 Fernandez et al. Nov 2007 A1
20070270943 Solem et al. Nov 2007 A1
20070293943 Quinn Dec 2007 A1
20090048668 Wilson et al. Feb 2009 A1
20090062836 Kurrus Mar 2009 A1
20090076600 Quinn Mar 2009 A1
20090177266 Powell et al. Jul 2009 A1
20100022823 Goldfarb et al. Jan 2010 A1
20100217283 St.Goar et al. Aug 2010 A1
20100298929 Thornton et al. Nov 2010 A1
20110029071 Zlotnick et al. Feb 2011 A1
20110066233 Thornton et al. Mar 2011 A1
20110106245 Miller et al. May 2011 A1
20110137397 Chau et al. Jun 2011 A1
20110218620 Meiri et al. Sep 2011 A1
20110224655 Asirvatham et al. Sep 2011 A1
20110264208 Duffy et al. Oct 2011 A1
20110313437 Yeh Dec 2011 A1
20110319989 Lane et al. Dec 2011 A1
20120010700 Spenser Jan 2012 A1
20120065464 Ellis et al. Mar 2012 A1
20120078360 Rafiee Mar 2012 A1
20120095547 Chuter Apr 2012 A1
20120116418 Belson et al. May 2012 A1
20120191181 Kassab et al. Jul 2012 A1
20120245678 Solem Sep 2012 A1
20120310334 Dolan Dec 2012 A1
20130018414 Widimski et al. Jan 2013 A1
20130030522 Rowe et al. Jan 2013 A1
20130197559 Hariton et al. Aug 2013 A1
20130226288 Goldwasser et al. Aug 2013 A1
20130253547 Goldfarb et al. Sep 2013 A1
20130261739 Kuehn Oct 2013 A1
20130338764 Thornton et al. Dec 2013 A1
20140039607 Kovach Feb 2014 A1
20140058502 Marchand et al. Feb 2014 A1
20140236198 Goldfarb et al. Aug 2014 A1
20140277426 Dakin et al. Sep 2014 A1
20140371789 Hariton et al. Dec 2014 A1
20150038988 Tegels et al. Feb 2015 A1
20150134057 Rourke et al. May 2015 A1
20150173765 Miller et al. Jun 2015 A1
20160324635 Vidlund Nov 2016 A1
20170100250 Marsot et al. Apr 2017 A1
20170143478 Schwartz et al. May 2017 A1
20170174979 Sanders Jun 2017 A1
20170216028 Khalil Aug 2017 A1
20170245988 Siegel et al. Aug 2017 A1
20170325842 Siegel et al. Nov 2017 A1
20180193016 Eigler et al. Jul 2018 A1
20180289478 Quill Oct 2018 A1
20190008638 Siegel et al. Jan 2019 A1
20190076246 Siegel Mar 2019 A1
20190298516 Siegel et al. Oct 2019 A1
20190343630 Kizuka Nov 2019 A1
20190365529 Siegel et al. Dec 2019 A1
20200030092 Tuval et al. Jan 2020 A1
20200121454 Spence Apr 2020 A1
20200375730 Siegel et al. Dec 2020 A1
20210030534 Siegel et al. Feb 2021 A1
20220226113 Siegel et al. Jul 2022 A1
Foreign Referenced Citations (26)
Number Date Country
106175986 Dec 2016 CN
1 674 040 Jun 2006 EP
1 539 015 Apr 2011 EP
3 269 330 Jan 2018 EP
H05-220174 Aug 1993 JP
2004-008805 Jan 2004 JP
2004-530451 Oct 2004 JP
2004-531337 Oct 2004 JP
2008-142563 Jun 2008 JP
2008-514307 Aug 2008 JP
WO 0060995 Oct 2000 WO
WO 0126557 Apr 2001 WO
WO 01 070116 Sep 2001 WO
WO 02034167 May 2002 WO
WO 03049619 Jun 2003 WO
WO 2004012583 Feb 2004 WO
WO 2005058239 Jun 2005 WO
WO 2007011994 Jan 2007 WO
WO 2011116379 Sep 2011 WO
WO 2014138284 Sep 2014 WO
WO 2014138482 Sep 2014 WO
WO 2016040526 Mar 2016 WO
WO 2016077783 May 2016 WO
WO 2017015632 Jan 2017 WO
WO 2018140535 Aug 2018 WO
WO 2019152598 Aug 2019 WO
Non-Patent Literature Citations (8)
Entry
Bhargava et al., “Biosense Left Ventricular Electromechanical Mapping”, Asian Cardiovasc Thorac Ann 1999, 7:345-52.
Black MD, M., Division of Pediatric Cardiac Surgery, Standford University School of Medicine, California, USA, Minimally Invasive Pediatric Cardiac Surgery, Online Article in 4 pages.
Ethicon Wound Closure Manual—Chapter 6, Research and Development at Ethicon, Inc.—An Ongoing Process of Change and Improvement, Online at www.ethiconinc.com in 4 pages.
Gersak MD, Ph.D., B., “Mitral Valve Repair or Replacement on the Beating Heart”, The Heart Surgery Forum #2000-1989, Jun. 8, 2000, pp. 232-237, 2000 Forum Multimedia Publishing, LLC.
Perclose A-T, 6F Suture-Mediated Closure (SMC) System, Instructions for Use disctributed in the U.S, by Abbott laboratories, Inc. 2002, 2006 Abbott Laboratories in 11 pages.
Quealy et al., “Use of Combined Intravascular Ultrasound and PTCA Catheter: Clinical Utility”, Chapter 12, pp. 245-250.
International Search Report and Written Opinion issued in PCT Application No. PCT/US2015/060726, dated Mar. 4, 2016, in 16 pages.
International Preliminary Reporton Patentability issued in PCT Application No. PCT/US2015/060726, dated May 16, 2017, in 10 pages.
Related Publications (1)
Number Date Country
20200367926 A1 Nov 2020 US
Provisional Applications (1)
Number Date Country
62079811 Nov 2014 US
Divisions (1)
Number Date Country
Parent 15525914 US
Child 16947730 US